TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older.~2. Ocular hypertension or open-angle glaucoma in both eyes.~3. Unmedicated intraocular pressure \> 17 mmHg in one or both eyes and \< 30 mmHg in both eyes.~4. Corrected visual acuity in each eye equivalent to 20/200 or better.~5. Able and willing to give signed informed consent and follow study instructions.~Exclusion Criteria:~1. Glaucoma with pseudoexfoliation or pigment dispersion component, history of angle closure, narrow angles.~2. Intraocular pressure ≥ 30 mmHg.~3. Use of ocular medications within 30 days.~4. Known hypersensitivity to any component of the test formulations or to medications used routinely during a clinical eye examination.~5. Previous eye surgery (other than cataract).~6. Ocular trauma within 6 months.~7. Clinically significant ocular disease that might interfere with the study.~8. Central corneal thickness greater than 620 µm.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil Ophthalmic Solution 0.02% (Type: EXPERIMENTAL): 1 drop in each eye (OU) daily
- Netarsudil Ophthalmic Solution Vehicle (Type: PLACEBO_COMPARATOR): 1 drop in each eye (OU) daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of advanced upper lobe emphysema~* age \>/= 40 years~* clinically significant dyspnea~* failure of standard medical therapy to relieve symptoms (inhaled beta agonist \& inhaled anticholinergic)~* pulmonary function tests within protocol-specified ranges (post bronchodilator FEV1 \< 45% predicted \& experiencing \< 30% or 300 mL improvement using bronchodilator; total lung capacity \> 110% predicted; residual volume \> 150% predicted)~* 6 Minute Walk Distance \>/= 150 m~Exclusion Criteria:~* alpha-1 protease inhibitor deficiency~* homogeneous emphysema~* tobacco use within 4 months of initial visit~* body mass index \< 15 kg/m2 or\> 35 kg/m2~* clinically significant asthma, chronic bronchitis or bronchiectasis~* allergy or sensitivity to procedural components~* pregnant, lactating or unwilling to use birth control if required~* prior lung volume reduction surgery, lobectomy, pneumonectomy, lung transplant, endotracheal valve placement, airway stent placement or pleurodesis~* comorbid condition that could adversely influence outcomes~* inability to tolerate bronchoscopy under conscious sedation (or anesthesia)~* history of renal infarction or renal failure

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Treatment will be administered in 2 treatment sessions.
- Group 2 (Type: EXPERIMENTAL): Treatment will be administered in a single treatment session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Office systolic blood pressure that remains ≥160 mmHg (≥150 mmHg for patient with type 2 diabetes) despite the stable use of ≥3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic, for a minimum of 14 days prior to enrollment~* Age ≥18 and ≤80 years old~* Able and willing to provide written informed consent to participate in the study~* Able and willing to comply with the required follow-up schedule~Exclusion Criteria:~* Prior renal artery intervention (balloon angioplasty or stenting)~* Evidence of renal artery atherosclerosis (defined as a stenotic severity of \>30%) in either renal artery~* Multiple main renal arteries in either kidney~* Main renal arteries \<4 mm in diameter or \<20 mm in length~* eGFR of \<45 mL/min per 1.73 m2 using the MDRD formula~* Type 1 diabetes~* Renovascular hypertension or hypertension secondary to other renal disorders (glomerulonephritis, polycystic kidney disease, end-stage renal failure)~* Others

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- renal artery ablation (Type: EXPERIMENTAL): Catheter-based RF ablation in renal artery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EPO2-A: Evaluation of Pre-Oxygenation in Morbid Obesity: Effect of Position and Positive Pressure Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI \> 40~* Abdominal obesity : waist circumference: \> 115 for the women waist circumference \> 130 for the men~Exclusion Criteria:~* Facial hair~* Cranio-facial abnormality~* Asthma (continuous treatment)~* COPD (FEV1 \< 80%)~* Severe cardiovascular disease (NYHA \> 3)~* Pregnancy~* Tobacco use~* Know or suspected difficulty with intubation~* Severe GERD or risk of aspiration

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Beach chair (BC) and ZEEP (Type: ACTIVE_COMPARATOR): Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
- Reverse Trendelenburg and NIPPV (Type: EXPERIMENTAL): Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Documented congenital C1-INH deficiency~* Acute facial or abdominal HAE attack~Key Exclusion Criteria:~* Acquired angioedema~* Treatment with any other investigational drug within the last 30 days before study entry~* Treatment with any C1-INH concentrate within the previous 7 days

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C1-INH 10 U/kg bw (Type: EXPERIMENTAL): 10 Units (U)/kg body weight (bw) dose
- C1-INH 20 U/kg bw (Type: EXPERIMENTAL): 20 U/kg bw dose
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients should have BMI \> 30kg/m²~* Present untreated diabetes mellitus type 2~* Age between 19 and 50 years~* Waist Circumference \> 80 cm~Exclusion Criteria:~* Renal, coronary vascular or peripheral, hematologic or hepatic disease~* Presence of severe hypertriglyceridemia (\> 400mg/dl)~* Smokers~* Significant body mass loss (\> 5%) within the six months prior to the study

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin 850mg/pill will be administered at lunch time and dinner time for 30 days
- Vildagliptina (Type: EXPERIMENTAL): Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥18 years,~* with the diagnosis of various types of cancers (such as lymphoma, breast, lung, testicular, prostate, ovary and gastrointestinal cancers), receiving first-line chemotherapy regimens with a high FN risk, which PegaGen® is injected due to physician decision.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes with HbA1c between 6.5% and 10% at screening with stable treatment for 3 months prior to randomization~* On one of the following anti-diabetes regimens with stable treatment for approximately 3 months prior to randomization: 1) metformin monotherapy; 2) DPP4 inhibitor agent monotherapy; 3) combination therapy of metformin and DPP4 inhibitor agent; 4) no anti-diabetes therapy.~* Body Mass Index of 28 to 40 kg/m2 at screening~* Body weight between 65 and 140 kg at screening~Exclusion Criteria:~* Women of child-bearing potential unless they are using highly effective methods of contraception~* Diabetes other than Type 2 such as Type 1 diabetes, surgically induced diabetes, brittle type 2 diabetes as per investigator judgement, history of severe hypoglycemic episodes in the year preceding screening or hypoglycemic unawareness~* History of clinically significant arrythmias, heart failure, unstable angina, myocardial infarction or stroke, coronary artery bypass graft surgery, or percutaneous coronary intervention, deep vein thrombosis/pulmonary embolism, valve disorders or defects, pulmonary hypertension within 6 months of screening or 1 year for drug-eluting stents~* Tachycardia~* Use of anti-obesity medications, nutritional supplements or over the counter products for weight loss within 3 months of screening~* Use of medications known to induce weight gain such as some anti-convulsant and psychotropic medications within 3 months of screening~* Any chronic active infection (e.g., HIV, Hepatitis B or C, tuberculosis, etc) or has received anti-HCV treatments within the previous 6 months.~* Uncontrolled thyroid disease. Stable euthyroid patients on stable thyroid replacement therapy for at least 3 months of screening are allowed.~* Abnormal liver function tests such as SGOT, SGPT, alkaline phosphatase, or serum bilirubin, or abnormal lipase and/or amylase.~* Known history or presence of severe active acute or chronic liver disease (e.g., cirrhosis).~* Uncontrolled depression~* Use of skeletal muscle anabolic agents in any form for 3 months prior to screening~* Chronic kidney disease \[estimated glomerular filtration rate (GFR) \< 30 mL/min\];

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BYM338 10 mg/kg (Type: EXPERIMENTAL): Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, every 4 weeks until week 44 (12 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to use COC for at least 6 cycles.~* 18 - 35 years of age at screening.~* Body Mass Index (BMI) of \>/= 17 and \</= 35.~* Good physical and mental health.~* Willing to use condoms as the sole contraceptive method during screening cycle and 1 post-treatment cycle.~* Willing to give informed consent.~Exclusion Criteria:~* Contraindications for contraceptive steroids (general).~* Additional contraindications (renal, hepatic or adrenal insufficiency).~* Breastfeeding.~* Present use (or use within 2 months prior to start of the trial medication) of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, sex~steroids (other than pre- and post treatment contraceptive method) and herbal remedies containing Hypericum perforatum (St. John's Wort).~* Administration of any other investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period.~* Abnormal cervical smear at screening, or documentation of an abnormal smear performed within 6 months before screening.~* Clinically relevant abnormal laboratory result at screening as judged by the investigator.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- NOMAC-E2 (Type: EXPERIMENTAL): Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
- DRSP-EE (Type: ACTIVE_COMPARATOR): Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have hypertrophic (raised) breast scars from previous surgery~* Subjects must be healthy~Exclusion Criteria:~* Currently pregnant or pregnant during the 6 months, prior to inclusion in the study or breast-feeding.~* Presence of history of breast cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): None
- Group 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* preterm premature rupture of membrane(PPROM), PA 22+0\~34+0wks~* ROM \<72 hrs before randomization~* cervical dilatation \<3cm~* uterine contraction less than 4 times per 1 hr~Exclusion Criteria:~* Major fetal malformation~* Rupture of the membrane \>72hrs before randomization~* Vaginal bleeding~* IIOC (incompetent internal os of cervix)~* Placenta previa~* Gestational diabetes or overt diabetes~* Hypertensive disorders in pregnancy~* Liver cirrhosis~* Acute renal failure

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- one-week treatment group (Type: ACTIVE_COMPARATOR): Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization for one week
- until-delivery treatment group (Type: ACTIVE_COMPARATOR): Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization until delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Preemptive Etoricoxib and Dexamethasone on Wound Healing and Clinical Parameters After Third Molar Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Systemically healthy individuals (ASA I by American Society of Anesthesiologists classification);~* Age 18-30 years;~* Absence of hypersensitivity to any of the medications in the study;~* Subjects capable to understand the protocol and sign an informed consent form.~Exclusion Criteria:~* Systemic disorders;~* Individuals in gestation or lactation period;~* Radiographic presence of potential cystic or tumorous lesions in the region of the extraction-required IMTM;~* Any symptoms or clinical signs of the infection caused by the extraction-required IMTM up to 10 days preoperatively;~* Use of NSAIDs or corticosteroids within 10 days before the surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Etoricoxib group (Type: ACTIVE_COMPARATOR): One hour preoperatively, preemptive, single-dose etoricoxib tablet in dosage of 90 mg will be administered orally
- Dexamethasone group (Type: ACTIVE_COMPARATOR): One hour preoperatively, preemptive, single-dose dexamethasone in dosage of 4 mg will be administered intramuscularly
- Control group (Type: NO_INTERVENTION): In this group, one hour preoperatively no medication will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of essential hypertension~* Treating physician has determined that pharmacologic therapy is necessary~Exclusion Criteria:~* Compelling indication to select one particular medication~* Specific contraindication for any of the 3 therapies

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Amlodipine, then HCTZ, then Lisinopril (Type: ACTIVE_COMPARATOR): Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
- Amlodipine, then Lisinopril, then HCTZ (Type: ACTIVE_COMPARATOR): Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
- HCTZ, then Amlodipine, then Lisinopril (Type: ACTIVE_COMPARATOR): Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
- HCTZ, then Lisinopril, then Amlodipine (Type: ACTIVE_COMPARATOR): Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
- Lisinopril, then Amlodipine, then HCTZ (Type: ACTIVE_COMPARATOR): Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
- Lisinopril, then HCTZ, then Amlodipine (Type: ACTIVE_COMPARATOR): Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed study B2061032 and who in the investigator's opinion, would benefit from long term treatment with DVS SR~* Willingness and ability to comply with scheduled visits, treatment plan, and procedures~Exclusion Criteria:~* Requires precaution against suicide~* Not in generally healthy medical condition~* Poor compliance with study drug or study procedures during participation in study B2061032

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine Succinate Sustained-Release (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete